Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04742075 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer

Study acronym: DOVACC
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 27, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruitingv7 Show 4 more changesShow less
    • Enrollment target: estimated 184 to confirmed 188
    • Primary completion date: Dec 31, 2026 to May 1, 2026
    • Eligibility criteria shortened, about 10 words
    • Site details revised
  2. Primary completion date: Dec 15, 2024 to Dec 31, 2026v6 Show 4 more changesShow less
    • Study completion date: Dec 15, 2026 to Dec 31, 2030
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 5 of 5 entries
    • Collaborators: 5 to 6
  3. Primary completion date: Jun 15, 2024 to Dec 15, 2024
    • Study completion date: Jun 15, 2026 to Dec 15, 2026
    v5
  4. Eligibility criteria expanded, about 113 words
    • Study description expanded, about 12 words
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 15, 2021 to Dec 15, 2021
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective, multicenter, open-label, randomized phase II maintenance study is evaluating the efficacy of UV1-olaparib-durvalumab combination as maintenance therapy after platinum combination therapy for BRCAwt patients with relapsed ovarian cancer.
Trial Details
NCT Number NCT04742075
Lead Sponsor Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators: North Eastern German Society of Gynaecological Oncology, Belgian Gynaecological Oncology Group, Hellenic Cooperative Oncology Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, European Network of Gynaecological Oncological Trial Groups (ENGOT), Dutch Gynaecological Oncology Group
Conditions
(from sponsor)		 Ovarian Cancer
Related terms Ovarian Neoplasms
Enrollment 188 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov